drugset / Trial / NCT02257580

The Effect of Intravenous EACA on Blood Loss and Transfusion Requirements After Bilateral VRO

NCT02257580 ↗

Phase 4 Completed 28 enrolled Hospital for Special Surgery, New York
RandomizedSingle-groupQuadruple-blindTreatment

Summary

E-Aminocaproic acid (EACA) is an anti-fibrinolytic agent that is used to decrease blood loss and transfusion requirements after several orthopedic procedures. The aim of this prospective double-blind placebo-controlled randomized trial is to determine whether IV EACA reduces intra-operative calculated total blood loss in patients undergoing bilateral varus rotational osteotomy (VRO). This study will also investigate intraoperative cell saver utilization, transfusion of allogeneic blood, hospital length-of-stay (LOS), short term complications, and long-term outcomes.This study will provide Level I evidence and has the potential to improve outcomes in children undergoing this procedure.

Timeline

Start
2015-04-01
Primary completion
2020-10-26
Completion
2020-10-26

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject E-Aminocaproic acid Small molecule 33 mg/kg Intravenous

Indications

No indication recorded.